tiprankstipranks
Pharmaron Beijing Co., Ltd. Class H (HK:3759)
:3759
Hong Kong Market
3759
Pharmaron Beijing Co., Ltd. Class H
RESEARCH TOOLSreports
Want to see HK:3759 full AI Analyst Report?

Pharmaron Beijing Co., Ltd. Class H (3759) Stock Forecast & Price Target

10 Followers
See the Price Targets and Ratings of:

3759 Analyst Ratings

Strong Buy
8Ratings
Strong Buy
8 Buy
0 Hold
0 Sell
Based on 8 analysts giving stock ratings to
Pharmaron
Beijing Co., Ltd. Class H
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

3759 Stock 12 Month Forecast

Average Price Target

HK$29.03
▲(20.25% Upside)
Based on 8 Wall Street analysts offering 12 month price targets for Pharmaron Beijing Co., Ltd. Class H in the last 3 months. The average price target is HK$29.03 with a high forecast of HK$32.50 and a low forecast of HK$26.00. The average price target represents a 20.25% change from the last price of HK$24.14.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"13":"HK$13","18":"HK$18","23":"HK$23","28":"HK$28","33":"HK$33"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":32.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">HK$32.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":29.02875,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">HK$29.03</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":26,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">HK$26.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[13,18,23,28,33],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.25,18.423076923076923,19.596153846153847,20.76923076923077,21.942307692307693,23.115384615384617,24.28846153846154,25.46153846153846,26.634615384615387,27.807692307692307,28.980769230769234,30.153846153846153,31.326923076923077,{"y":32.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.25,18.15605769230769,19.062115384615385,19.968173076923076,20.87423076923077,21.78028846153846,22.686346153846152,23.592403846153843,24.498461538461537,25.404519230769232,26.310576923076923,27.216634615384613,28.122692307692304,{"y":29.02875,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,17.25,17.923076923076923,18.596153846153847,19.26923076923077,19.942307692307693,20.615384615384617,21.28846153846154,21.96153846153846,22.634615384615387,23.307692307692307,23.980769230769234,24.653846153846153,25.326923076923077,{"y":26,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":14.527,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":16.363,"date":1751328000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":21.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":22.36,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":28.44,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":26.02,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.88,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.59,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":20,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":18.83,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.88,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":21.04,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.25,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price TargetHK$32.50Average Price TargetHK$29.03Lowest Price TargetHK$26.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on HK:3759
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
HK$31
Buy
28.42%
Upside
Reiterated
05/28/26
Morgan Stanley Sticks to Its Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)
BOCOM International Holdings Company Analyst forecast on HK:3759
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$32.5
Buy
34.63%
Upside
Reiterated
05/04/26
BOCOM International Holdings Company Sticks to Its Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)
Bank of China Analyst forecast on HK:3759
Unknown Analyst
Bank of China
Not Ranked
Bank of China
HK$26
Buy
7.71%
Upside
Reiterated
05/02/26
Bank of China Sticks to Their Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)
Goldman Sachs Analyst forecast on HK:3759
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
HK$29.7
Buy
23.03%
Upside
Reiterated
04/29/26
Goldman Sachs Sticks to Its Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)
UBS Analyst forecast on HK:3759
Unknown Analyst
UBS
Not Ranked
UBS
HK$32.9→HK$30.1
Buy
24.69%
Upside
Reiterated
04/28/26
Pharmaron Beijing Co., Ltd. Class H (17Q1) Receives a Buy from UBS
CLSA Analyst forecast on HK:3759
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$28.6
Buy
18.48%
Upside
Reiterated
04/28/26
CLSA Reaffirms Their Buy Rating on Pharmaron Beijing Co., Ltd. Class H (17Q1)
Bank of America Securities Analyst forecast on HK:3759
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
HK$27
Buy
11.85%
Upside
Reiterated
03/31/26
Bank of America Securities Remains a Buy on Pharmaron Beijing Co., Ltd. Class H (17Q1)
Nomura Analyst forecast on HK:3759
Unknown Analyst
Nomura
Not Ranked
Nomura
HK$27.33
Buy
13.21%
Upside
Reiterated
03/31/26
Pharmaron Beijing Co., Ltd. Class H (17Q1) Receives a Buy from Nomura
Huatai Securities Analyst forecast on HK:3759
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
HK$28.54→HK$33.69
Buy
39.56%
Upside
Reiterated
10/29/25
HSBC Analyst forecast on HK:3759
Linda Shu
HSBC
HSBC
HK$28.1
Buy
16.40%
Upside
Reiterated
10/15/25
Citi Analyst forecast on HK:3759
Ruili Bian
Citi
Citi
HK$33→HK$39
Buy
61.56%
Upside
Reiterated
08/25/25
Pharmaron Beijing Co., Ltd. Class H (17Q1) Receives a Buy from Citi
CICC Analyst forecast on HK:3759
Unknown Analyst
CICC
Not Ranked
CICC
HK$26
Buy
7.71%
Upside
Reiterated
08/22/25
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Morgan Stanley Analyst forecast on HK:3759
Unknown Analyst
Morgan Stanley
Not Ranked
Morgan Stanley
HK$31
Buy
28.42%
Upside
Reiterated
05/28/26
Morgan Stanley Sticks to Its Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)
BOCOM International Holdings Company Analyst forecast on HK:3759
Unknown Analyst
BOCOM International Holdings Company
Not Ranked
BOCOM International Holdings Company
HK$32.5
Buy
34.63%
Upside
Reiterated
05/04/26
BOCOM International Holdings Company Sticks to Its Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)
Bank of China Analyst forecast on HK:3759
Unknown Analyst
Bank of China
Not Ranked
Bank of China
HK$26
Buy
7.71%
Upside
Reiterated
05/02/26
Bank of China Sticks to Their Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)
Goldman Sachs Analyst forecast on HK:3759
Unknown Analyst
Goldman Sachs
Not Ranked
Goldman Sachs
HK$29.7
Buy
23.03%
Upside
Reiterated
04/29/26
Goldman Sachs Sticks to Its Buy Rating for Pharmaron Beijing Co., Ltd. Class H (17Q1)
UBS Analyst forecast on HK:3759
Unknown Analyst
UBS
Not Ranked
UBS
HK$32.9→HK$30.1
Buy
24.69%
Upside
Reiterated
04/28/26
Pharmaron Beijing Co., Ltd. Class H (17Q1) Receives a Buy from UBS
CLSA Analyst forecast on HK:3759
Unknown Analyst
CLSA
Not Ranked
CLSA
HK$28.6
Buy
18.48%
Upside
Reiterated
04/28/26
CLSA Reaffirms Their Buy Rating on Pharmaron Beijing Co., Ltd. Class H (17Q1)
Bank of America Securities Analyst forecast on HK:3759
Unknown Analyst
Bank of America Securities
Not Ranked
Bank of America Securities
HK$27
Buy
11.85%
Upside
Reiterated
03/31/26
Bank of America Securities Remains a Buy on Pharmaron Beijing Co., Ltd. Class H (17Q1)
Nomura Analyst forecast on HK:3759
Unknown Analyst
Nomura
Not Ranked
Nomura
HK$27.33
Buy
13.21%
Upside
Reiterated
03/31/26
Pharmaron Beijing Co., Ltd. Class H (17Q1) Receives a Buy from Nomura
Huatai Securities Analyst forecast on HK:3759
Unknown Analyst
Huatai Securities
Not Ranked
Huatai Securities
HK$28.54→HK$33.69
Buy
39.56%
Upside
Reiterated
10/29/25
HSBC Analyst forecast on HK:3759
Linda Shu
HSBC
HSBC
HK$28.1
Buy
16.40%
Upside
Reiterated
10/15/25
Citi Analyst forecast on HK:3759
Ruili Bian
Citi
Citi
HK$33→HK$39
Buy
61.56%
Upside
Reiterated
08/25/25
Pharmaron Beijing Co., Ltd. Class H (17Q1) Receives a Buy from Citi
CICC Analyst forecast on HK:3759
Unknown Analyst
CICC
Not Ranked
CICC
HK$26
Buy
7.71%
Upside
Reiterated
08/22/25
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Pharmaron Beijing Co., Ltd. Class H

3 Months
Linda ShuHSBC
Success Rate
1/3 ratings generated profit
33%
Average Return
-5.30%
Copying Linda Shu's trades and holding each position for 3 Months would result in 33.33% of your transactions generating a profit, with an average return of -5.30% per trade.
1 Year
Google Health Care EUTipRanks - Google
Success Rate
0/2 ratings generated profit
0%
Average Return
-7.05%
Copying Google Health Care EU's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -7.05% per trade.
2 Years
Google Health Care EUTipRanks - Google
Success Rate
0/2 ratings generated profit
0%
Average Return
-7.05%
Copying Google Health Care EU's trades and holding each position for 2 Years would result in 0.00% of your transactions generating a profit, with an average return of -7.05% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

3759 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
1
2
4
3
Buy
0
2
6
7
5
Hold
0
0
0
0
0
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
0
3
8
11
8
In the current month, 3759 has received 8 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. 3759 average Analyst price target in the past 3 months is 29.03.
Each month's total comprises the sum of three months' worth of ratings.

3759 Financial Forecast

3759 Earnings Forecast

Next quarter’s earnings estimate for 3759 is HK$0.29 with a range of HK$0.29 to HK$0.29. The previous quarter’s EPS was HK$0.21. 3759 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 3759 has Performed in-line its overall industry.
Next quarter’s earnings estimate for 3759 is HK$0.29 with a range of HK$0.29 to HK$0.29. The previous quarter’s EPS was HK$0.21. 3759 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year 3759 has Performed in-line its overall industry.

3759 Sales Forecast

Next quarter’s sales forecast for 3759 is HK$4.45B with a range of HK$4.45B to HK$4.45B. The previous quarter’s sales results were HK$4.04B. 3759 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 3759 has Performed in-line its overall industry.
Next quarter’s sales forecast for 3759 is HK$4.45B with a range of HK$4.45B to HK$4.45B. The previous quarter’s sales results were HK$4.04B. 3759 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year 3759 has Performed in-line its overall industry.

3759 Stock Forecast FAQ

What is HK:3759’s average 12-month price target, according to analysts?
Based on analyst ratings, Pharmaron Beijing Co., Ltd. Class H’s 12-month average price target is 29.03.
    What is HK:3759’s upside potential, based on the analysts’ average price target?
    Pharmaron Beijing Co., Ltd. Class H has 20.25% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Pharmaron Beijing Co., Ltd. Class H a Buy, Sell or Hold?
          Pharmaron Beijing Co., Ltd. Class H has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Pharmaron Beijing Co., Ltd. Class H’s share price target?
            The average share price target for Pharmaron Beijing Co., Ltd. Class H is 29.03. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is HK$32.50 ,and the lowest forecast is HK$26.00. The average share price target represents 20.25% Increase from the current price of HK$24.14.
              What do analysts say about Pharmaron Beijing Co., Ltd. Class H?
              Pharmaron Beijing Co., Ltd. Class H’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.
                How can I buy shares of Pharmaron Beijing Co., Ltd. Class H?
                To buy shares of HK:3759, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.